Product Pathways - Growth Factors/Cytokines
Human Interleukin-28A (hIL-28A/IFN-λ2) #5164
|5164LF||50 µg (Carrier Free)||---||In Stock||---|
|5164LC||50 µg (With Carrier)||---||In Stock||---|
|5164SF||10 µg (Carrier Free)||---||In Stock||---|
|5164SC||10 µg (With Carrier)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-28A (hIL-28A) Val26-Val200 (Accession #NP_742150) was expressed in human 293 cells at Cell Signaling Technology.
Based on amino acid sequencing, greater than 60% of recombinant hIL-28A starts at Val26 (VPVAR) and has a calculated MW of 19,754. The remainder starts at Pro27 (PVARL) or Val28 (VARLH). DTT-reduced and non-reduced protein migrate as 21 kDa polypeptides.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-28A. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-28A was determined in a virus protection assay. The ED50 of each lot is between 10-60 ng/ml.
The purity of recombinant hIL-28A was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-28A and staining overnight with Coomassie Blue.
The bioactivity of hIL-28A was determined in a virus protection assay. Hep G2 cells were pre-treated with increasing concentrations of hIL-28A for 24 hours. Cells were then inoculated with encephalomyocarditis virus (EMCV) and incubated for an additional 48 hours. Surviving cells were fixed and stained with crystal violet and the OD595 was determined.
Western blot analysis of extracts from Hep G2 cells, untreated or treated with hIL-28A for 30 minutes, using Phospho-Stat3 (Tyr705) (D3A7) Rabbit mAb #9145 (upper) and Stat3 Antibody #9132 (lower).
Less than 0.01 ng endotoxin/1 μg hIL-28A.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-28A. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-28A is a member of the Interferon λ family of cytokines, which includes IL-29 and IL-28B (1). IL-28A is produced by a number of cell types and shares many functions with Type I Interferons (1-3). IL-28A exhibits anti-viral activities in vitro and in vivo (1,2). IL-28A directly inhibits tumor cell proliferation and promotes anti-tumor immune responses in vivo (1,3). The IL-28 receptor is a heterodimer of the IL28-Rα and IL10-RI (1). IL-28A activates Stat1, Stat3, and Stat5 (1). IL-28Rα expression is limited to a few cell types, including plasmacytoid DC and epithelial cells (1).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.